膀胱移行细胞癌多药耐药基因与p53基因表达的临床研究

Study on the MDR1 and p53 Gene Expression in Bladder Transitional Cell Carcinoma

【目的】探讨膀胱癌中多药耐药基因(MDR1)与p53基因表达的临床意义。【方法】采用免疫组化(SABC)法对32例膀胱移行细胞癌中MDR1表达产物P-GP与p53基因产物p53蛋白进行了检测。【结果】32例膀胱移行细胞癌中P-GP、p53阳性率分别为41.0%和47.0%,且随膀胱癌的病理分级和临床分期而增高。T2~T4期同Tis^T1期相比,MDR1及p53的表达均差异有显著性。【结论】临床检测MDR1及p53可对膀胱癌患者提供更多的预后信息。

[Objective]To study the clinical significance of the expression of multidrug resistance gene （MDR1）and p53 gene in bladder transitional cell carcinoma（BTCC）. [Methods]P-GP and p53 proteins were detected by immunohistochemical（SABC）methods in 32 BTCC specimens. [Results]The positive staining of P- GP and p53 was 40% and 48.6% of all the specimens. The expression of MDR1 and p53 had a statistical significant difference between stages T2～T4 and Tis～T1 BTCC. [Conclusion]The coexpression of MDR1 and p53 may contribute to the prognostic value of BTCC.